tepmetko 225 mg compresse rivestite con film
merck (schweiz) ag - tepotinibum - compresse rivestite con film - tepotinibum 225 mg ut tepotinibi hydrochloridum monohydricum 250 mg, mannitolum 455.33 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, lactosum monohydricum 4.37 mg, macrogola, triacetinum, e 171, e 172 (rubrum), pro compresso obducto. - behandlung von nicht-kleinzelligem lungenkarzinom mit met-alterationen - synthetika
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - carcinoma, polmone non a piccole cellule - agenti antineoplastici - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
erlotinib sandoz 25 mg compresse rivestite con film
sandoz pharmaceuticals ag - erlotinibum - compresse rivestite con film - erlotinibum 25 mg ut erlotinibi hydrochloridum, lactosum monohydricum 23.98 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 0.2 mg. - onkologikum - synthetika
erlotinib sandoz 100 mg compresse rivestite con film
sandoz pharmaceuticals ag - erlotinibum - compresse rivestite con film - erlotinibum 100 mg ut erlotinibi hydrochloridum, lactosum monohydricum 95.93 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 0.7 mg. - onkologikum - synthetika
erlotinib sandoz 150 mg compresse rivestite con film
sandoz pharmaceuticals ag - erlotinibum - compresse rivestite con film - erlotinibum 150 mg ut erlotinibi hydrochloridum, lactosum monohydricum 143.9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 1.1 mg. - onkologikum - synthetika
erlotinib mylan
mylan s.p.a. - erlotinib - erlotinib
erlotinib sun
sun pharmaceutical industries (europe) b.v. - erlotinib - erlotinib
erlotinib sandoz
sandoz s.p.a. - erlotinib - erlotinib
nilotinib sandoz 200 mg capsule
sandoz pharmaceuticals ag - nilotinibum - capsule - nilotinibum 200 mg per nilotinibi hydrochloridum monohydricum, lactosum monohydricum 156.11 mg, crospovidonum, poloxamerum 188, silice colloidalis anhydrica, magnesio stearas, kapselhülle: gelatina, e-171, e 172 (giallo), drucktinte: lacca, propylenglycolum, ammoniae soluzione concentrata, kalii hydroxidum, e 172 (rosso) e 172 (nero), e 171, di una piccola scatola. - trattamento della leucemia mieloide cronica - synthetika
nilotinib sandoz 150 mg capsule
sandoz pharmaceuticals ag - nilotinibum - capsule - nilotinibum 150 mg per nilotinibi hydrochloridum monohydricum, lactosum monohydricum 117.08 mg, crospovidonum, poloxamerum 188, silice colloidalis anhydrica, magnesio stearas, kapselhülle: gelatina, e-171, e-172 (rosso) e 172 (giallo), drucktinte: lacca, e 172 (nero), propylenglycolum, ammoniae soluzione del 28 per cento, per una piccola scatola. - trattamento della leucemia mieloide cronica - synthetika